CHRISTINE MAZZOLA: Open Payments
NPI 1669471314 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,009 in 113 payments from 23 companies in 2025. Trend: 2023 $1,530 · 2024 $1,826 · 2025 $2,009
Food & beverage: $2,009
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $307 |
| AstraZeneca Pharmaceuticals LP | 12 | $306 |
| Novo Nordisk Inc | 17 | $290 |
| Otsuka America Pharmaceutical, Inc. | 15 | $192 |
| Abbott Laboratories | 9 | $152 |
| GlaxoSmithKline, LLC. | 11 | $149 |
| Astellas Pharma US Inc | 4 | $82 |
| Phathom Pharmaceuticals, Inc. | 4 | $61 |
| Exact Sciences Corporation | 3 | $53 |
| Merck Sharp & Dohme LLC | 3 | $51 |
Products named: REXULTI, FREESTYLE LIBRE 3, BREZTRI, VRAYLAR, QULIPTA, FARXIGA, TRELEGY ELLIPTA, Rybelsus.
Industry payments across DE — which companies pay providers there.
